October 2023 Br J Cardiol 2023;30:151 doi:10.5837/bjc.2023.031
Helen Alexander, Andrew D’Silva, Christopher Tack, Aynsley Cowie
Introduction The COVID-19 pandemic resulted in significant disruption to the delivery of cardiovascular rehabilitation (CR) services in the UK, following staff redeployment to acute services and limited access to workspaces.1 With restrictions being placed on face-to-face services due to concerns about safety and disease transmission, many CR services rapidly moved to remote delivery.2 These adjustments led to a significant drop in group-based exercise (–36%) and group-based education (–29%) with a corresponding increase (+16%) in CR staff supported self-managed options.3 In the future, those with cardiovascular disease are likely to be
June 2023 Br J Cardiol 2023;30:56–61 doi:10.5837/bjc.2023.016
Natalie Kilner, Sharlene Greenwood, Janet Cable, Iain Waite
Introduction Cardiac rehabilitation (CR) is a multi-factorial intervention incorporating education, physical activity and psychosocial support to address the risk factors for cardiovascular disease (CVD) and improve health behaviour.1,2 A recent Cochrane review evaluating 85 randomised-controlled trials concluded that the benefits of exercise-based CR include reduced mortality, lowering hospital admissions, and may improve health-related quality of life.3 Research by Hinde et al. suggests the achievement of 85% engagement in CR could see a reduction of 49,000 hospital admissions and 19,500 fewer deaths over 10 years, saving millions in costs
November 2022 Br J Cardiol 2022;29:137–40 doi:10.5837/bjc.2022.034
Claire Jones
Introduction Claire Jones Research suggests that globally, attainment of lipid targets is poor, with significant scope for improved optimisation of lipid lowering therapy (LLT) and cardiovascular (CV) risk factor management. Evidence suggests that the key initiating event in atherogenesis is retention of low-density lipoprotein cholesterol (LDL-C). To align with this, the European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) proposed new LDL-C goals in 2019,1 and revised CV risk stratification guidance (particularly relevant to high-risk and very high-risk patients). National Institute for Health and Care Excellence (N
August 2022 Br J Cardiol 2022;29:106–8 doi:10.5837/bjc.2022.027
Cong Ying Hey
Introduction Dr Cong Ying Hey Disparities in cardiovascular (CV) morbidity and mortality are among the major health and social care concerns in our modern society. In the UK, people living in the most deprived areas are four times more likely to die prematurely from CV disease (CVD) than those living in the least deprived areas.1 To address the disparities in CV outcomes, it is imperative to recognise the presence of inequalities at different interfaces of cardiology services. This article, therefore, aims to provide a focused discussion concerning potential measures to reduce health inequalities in cardiology through the lens of the challeng
March 2021 Br J Cardiol 2021;28:29–32 doi:10.5837/bjc.2021.013
Alexandra Palma, Charlotte Pereira, Heather Probert, Harriet Shannon
Introduction Completion of a functional capacity test before cardiac rehabilitation (CR) is one of the British Association for Cardiovascular Prevention and Rehabilitation (BACPR) Standards.1 The incremental shuttle walk test (ISWT) is an externally paced submaximal walking test with strong reliability, test–retest reliability, validity and responsiveness in cardiac populations.2,3 It is a test that is widely used to inform both risk stratification for cardiovascular events during CR, and for exercise prescription. The use of an electrocardiogram (ECG) to monitor the safety of the ISWT (indicated by the absence of major ECG changes) has not
June 2020 Br J Cardiol 2020;27:50 doi:10.5837/bjc.2020.019
Professor Susan Dawkes (Edinburgh Napier University / British Association for Cardiovascular Prevention and Rehabilitation [BACPR]), Sally Hughes (British Heart Foundation), Professor Simon Ray (British Cardiovascular Society), Dr Simon Nichols (Sheffield Hallam University / BACPR), Sally Hinton (BACPR), Ceri Roberts (North Bristol NHS Trust / BACPR), Dr Tom Butler (University of Chester / BACPR), Dr Hayes Delal (Royal Cornwall Hospitals NHS Trust / BACPR), Professor Patrick Docherty (University of York / National Audit of Cardiac Rehabilitation)
With thanks to:
Richard Forsyth (British Heart Foundation), Professor Rod Taylor (University of Glasgow), Professor Lis Neubeck (Edinburgh Napier University), Dr Scott Murray (Wirral University Teaching Hospital NHS Foundation Trust/ BACPR), Gill Farthing (Hampshire Hospitals NHS Foundation Trust / BACPR), Simone Meldrum (West Suffolk Community Cardiac Rehabilitation / BACPR), Tracy Kitto (East London NHS Foundation Trust / BACPR), Ruby Miller (Cwm Taf Morgannwg University Health Board / BACPR), Alison Allen (Prince Charles Hospital / BACPR)
“The COVID-19 pandemic is arguably one of the greatest public health challenges of our time, however, cardiovascular disease (CVD) remains the most common global cause of morbidity and mortality with over 18 million deaths per year. Understandably, hospitals have postponed non-critical services so that healthcare professionals can be deployed to areas dealing with patients who have the COVID-19 virus. However, there remains an ongoing need to assess, support and rehabilitate those who have CVD or are newly diagnosed with it to prevent the significant risk of unintended, yet significant consequences in the long-term. The consequence of withd
June 2020 Br J Cardiol 2020;27:67–70 doi:10.5837/bjc.2020.020
Mark Mills, Elizabeth Johnson, Hamza Zafar, Andrew Horwood, Nicola Lax, Sarah Charlesworth, Anna Gregory, Justin Lee, Jonathan Sahu, Graeme Kirkwood, Nicholas Kelland, Andreas Kyriacou
Introduction Atrial fibrillation (AF) is the most common cardiac rhythm disturbance in adults, estimated to affect 3.29% of the population in the UK in 2016.1 The condition is strongly associated with increased cardiovascular morbidity and mortality, in addition to reduced quality of life.2 The healthcare costs of managing patients with AF are high: estimates of the direct cost in Western Europe range from €450 to €3,000 per patient-year.3 Exercise-based cardiac rehabilitation is an established intervention in the management of several cardiovascular conditions, including coronary artery disease4 and heart failure.5 There is increasing re
December 2015 Br J Cardiol 2015;22:158 doi:10.5837/bjc.2015.043
M Justin S Zaman on behalf of all ACRAN healthcare professionals
Introduction ACRAN healthcare team Cardiac rehabilitation (CR) services are comprehensive, long-term programmes involving medical evaluation, prescribed exercise, cardiac risk factor modification, education and counselling. CR has been extensively reviewed in the literature,1 and, in patients after myocardial infarction, has been shown to reduce all-cause and cardiovascular mortality rates in a Cochrane review.2 However, it has also been shown by others to have little effect on outcomes.3 Doubts over the efficacy of CR have led commissioners to question the value of such services. While the debate continues, the Anglia region CR services (reb
December 2013 Br J Cardiol 2013;20(suppl 3):S1–S19
Kornelia Kotseva, Mary Seed, David Wood
Promoting cardiovascular health is central to the national strategy to reduce premature mortality in our population. In this supplement, we offer a new approach to cardiovascular disease (CVD) prevention through the MyAction preventive cardiology programme, developed by Imperial College London. This nurse-led, multi-disciplinary, family-centred service embraces all patients with atherosclerotic disease – coronary heart disease, stroke and peripheral arterial disease – together with those identified through Health Checks to be at high risk of developing CVD in one community-based programme. In this supplement, we describe the studies that
December 2013 Br J Cardiol 2013;20(suppl 3):S1–S19 doi:10.5837/bjc.2013.s03
David A Wood Full author details can be found here.
Introduction Cardiovascular diseases (CVDs) are a single family of diseases with common antecedents requiring a holistic approach to prevention. This is the central theme of the new cardiovascular outcomes strategy for NHS England.1 Atherosclerosis is ubiquitous in the population, manifesting itself in different ways – acute coronary syndromes, transient cerebral ischaemia or claudication – but linked by a common pathology and underlying causes in terms of lifestyle and related risk factors. Many with one expression of this disease commonly suffer from another, and yet each is managed in silos of care through cardiology, stroke and vascul
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits